Cartesian Therapeutics develops mRNA-based cell therapies for autoimmune diseases, starting with its lead candidate for myasthenia gravis. RNAC reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 29 | Needham | Reiterated | Buy | |
| Jun 9 | BTIG | Reiterated | Buy | |
| May 26 | Needham | Maintained | Buy |
Seasonality
How RNAC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
Whale Options Flow
90DNo whale options trades in RNAC in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNAC is in one of them and how their past RNAC trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RNAC in an article yet. Here's the latest on the wider market.
About Cartesian Therapeutics
Cartesian Therapeutics is a biotechnology company based in Frederick, Maryland, that is developing cell therapies for autoimmune diseases. Its approach uses mRNA to deliver a chimeric antigen receptor into a patient's own immune cells, which are then returned to the patient for outpatient treatment. Its lead product candidate, Descartes-08, is in clinical development for myasthenia gravis and certain myositis conditions. The company's target customers are patients with these conditions, and its products are not yet approved for sale.
- Headquarters
- Frederick, MD
- Founded
- 2008
- Website
- selectabio.com ↗